{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T02:59:25Z","timestamp":1792119565291,"version":"4.4.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2003,8,1]],"date-time":"2003-08-01T00:00:00Z","timestamp":1059696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2003,8,1]],"date-time":"2003-08-01T00:00:00Z","timestamp":1059696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2003,8]]},"DOI":"10.1124\/jpet.103.050682","type":"journal-article","created":{"date-parts":[[2003,7,18]],"date-time":"2003-07-18T23:17:37Z","timestamp":1058570257000},"page":"581-587","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Suppressed Prolactin Response to Dynorphin A1\u201313 in Methadone-Maintained Versus Control Subjects"],"prefix":"10.1016","volume":"306","author":[{"given":"Gavin","family":"Bart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Borg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H.","family":"Schluger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Jeanne","family":"Kreek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.103.050682_bib1","doi-asserted-by":"crossref","unstructured":"Butelman ER, Ball JW, and Kreek MJ (2002) Comparison of the discriminative and neuroendocrine effects of centrally penetrating \u03ba-opioid agonists in rhesus monkeys. Psychopharmacology 164: 115\u2013120.","DOI":"10.1007\/s00213-002-1195-y"},{"key":"10.1124\/jpet.103.050682_bib2","doi-asserted-by":"crossref","unstructured":"Butelman ER, Harris TJ, Perez A, and Kreek MJ (1999) Effects of systemically administered dynorphin A(1\u201317) in rhesus monkeys. J Pharmacol Exp Ther 290: 678\u2013686.","DOI":"10.1016\/S0022-3565(24)34950-X"},{"key":"10.1124\/jpet.103.050682_bib3","doi-asserted-by":"crossref","unstructured":"Butelman ER and Kreek MJ (2001) \u03ba-Opioid receptor agonist-induced prolactin release in primates is blocked by dopamine D2-like receptor agonists. Eur J Pharmacol 423: 243\u2013249.","DOI":"10.1016\/S0014-2999(01)01121-9"},{"key":"10.1124\/jpet.103.050682_bib4","doi-asserted-by":"crossref","unstructured":"Chavkin C, James IF, and Goldstein A (1982) Dynorphin is a specific endogenous ligand of the \u03ba opioid receptor. Science (Wash DC) 215: 413\u2013415.","DOI":"10.1126\/science.6120570"},{"key":"10.1124\/jpet.103.050682_bib5","doi-asserted-by":"crossref","unstructured":"Chou JZ, Chait BT, Wang R, and Kreek MJ (1996) Differential biotransformation of dynorphin A(1\u201317) and dynorphin A(1\u201313) peptides in human blood, ex vivo. Peptides 17: 983\u2013990.","DOI":"10.1016\/0196-9781(96)00154-4"},{"key":"10.1124\/jpet.103.050682_bib6","unstructured":"Claye LH, Maisonneuve IM, Yu J, Ho A, and Kreek MJ (1997) Local perfusion of dynorphin A1\u201317 reduces extracellular dopamine levels in the nucleus accumbens. NIDA Res Monogr 174: 113."},{"key":"10.1124\/jpet.103.050682_bib7","unstructured":"Cushman P Jr and Kreek MJ (1974) Methadone-maintained patients. Effect of methadone on plasma testosterone, FSH, LH and prolactin. NY State J Med 74: 1970\u20131973."},{"key":"10.1124\/jpet.103.050682_bib8","doi-asserted-by":"crossref","unstructured":"Deyo SN, Swift RM, and Miller RJ (1979) Morphine and endorphins modulate dopamine turnover in rat median eminence. Proc Natl Acad Sci USA 76: 3006\u20133009.","DOI":"10.1073\/pnas.76.6.3006"},{"key":"10.1124\/jpet.103.050682_bib9","doi-asserted-by":"crossref","unstructured":"Di Chiara G and Imperato A (1988) Opposite effects of \u03bc and \u03ba opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J Pharmacol Exp Ther 244: 1067\u20131080.","DOI":"10.1016\/S0022-3565(25)24578-5"},{"key":"10.1124\/jpet.103.050682_bib10","doi-asserted-by":"crossref","unstructured":"Durham RA, Johnson JD, Moore KE, and Lookingland KJ (1996) Evidence that D2 receptor-mediated activation of hypothalamic tuberoinfundibular dopaminergic neurons in the male rat occurs via inhibition of tonically active afferent dynorphinergic neurons. Brain Res 732: 113\u2013120.","DOI":"10.1016\/0006-8993(96)00501-X"},{"key":"10.1124\/jpet.103.050682_bib11","doi-asserted-by":"crossref","unstructured":"Frantz AG (1978) Prolactin. N Engl J Med 298: 201\u2013207.","DOI":"10.1056\/NEJM197801262980408"},{"key":"10.1124\/jpet.103.050682_bib12","doi-asserted-by":"crossref","unstructured":"Freeman ME, Kanyicska B, Lerant A, and Nagy G (2000) Prolactin: structure, function and regulation of secretion. Physiol Rev 80: 1523\u20131631.","DOI":"10.1152\/physrev.2000.80.4.1523"},{"key":"10.1124\/jpet.103.050682_bib13","doi-asserted-by":"crossref","unstructured":"Gambus PL, Schnider TW, Minto CF, Youngs EJ, Billard V, Brose WG, Hochhaus G, and Shafer SL (1998) Pharmacokinetics of intravenous dynorphin A(1\u201313) in opioid-naive and opioid-treated human volunteers. Clin Pharmacol Ther 64: 27\u201338.","DOI":"10.1016\/S0009-9236(98)90019-4"},{"key":"10.1124\/jpet.103.050682_bib14","doi-asserted-by":"crossref","unstructured":"Hurd YL (1996) Differential messenger RNA expression of prodynorphin and proenkephalin in the human brain. Neuroscience 72: 767\u2013783.","DOI":"10.1016\/0306-4522(96)00002-4"},{"key":"10.1124\/jpet.103.050682_bib15","doi-asserted-by":"crossref","unstructured":"Inturrisi CE and Verebely K (1972) The levels of methadone in the plasma in methadone maintenance. Clin Pharmacol Ther 13: 633\u2013637.","DOI":"10.1002\/cpt1972135part1633"},{"key":"10.1124\/jpet.103.050682_bib16","doi-asserted-by":"crossref","unstructured":"King AC, Ho A, Schluger J, Borg L, and Kreek MJ (1999) Acute subjective effects of dynorphin A(1\u201313) infusion in normal healthy subjects. Drug Alcohol Depend 54: 87\u201390.","DOI":"10.1016\/S0376-8716(98)00150-1"},{"key":"10.1124\/jpet.103.050682_bib17","doi-asserted-by":"crossref","unstructured":"Kling MA, Carson RE, Borg L, Zametkin A, Matochik JA, Schluger J, Herscovitch P, Rice KC, Ho A, Eckelman WC, et al. (2000) Opioid receptor imaging with positron emission tomography and [18F]cyclofoxy in long-term, methadone-treated former heroin addicts. J Pharmacol Exp Ther 295: 1070\u20131076.","DOI":"10.1016\/S0022-3565(24)39007-X"},{"key":"10.1124\/jpet.103.050682_bib18","unstructured":"Kreek MJ (1973) Plasma and urine levels of methadone. Comparison following four medication forms used in chronic maintenance treatment. NY State J Med 73: 2773\u20132777."},{"key":"10.1124\/jpet.103.050682_bib19","doi-asserted-by":"crossref","unstructured":"Kreek MJ (1978) Medical complications in methadone patients. Ann NY Acad Sci 311: 110\u2013134.","DOI":"10.1111\/j.1749-6632.1978.tb16769.x"},{"key":"10.1124\/jpet.103.050682_bib20","doi-asserted-by":"crossref","unstructured":"Kreek MJ, Borg L, Zhou Y, and Schluger J (2002) Relationships between endocrine functions and substance abuse syndromes: heroin and related short-acting opiates in addiction contrasted with methadone and other long-acting agonists used in pharmacotherapy of addiction, in Hormones, Brain and Behavior (Pfaff DW, Arnold AP, Etgen AM, Fahrbach SE, and Rubin RT eds) pp 781\u2013830, Academic Press, New York.","DOI":"10.1016\/B978-012532104-4\/50108-6"},{"key":"10.1124\/jpet.103.050682_bib21","doi-asserted-by":"crossref","unstructured":"Kreek MJ, Schluger J, Borg L, Gunduz M, and Ho A (1999) Dynorphin A1\u201313 causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: gender differences and implications for modulation of dopaminergic tone in the treatment of addictions. J Pharmacol Exp Ther 288: 260\u2013269.","DOI":"10.1016\/S0022-3565(24)37950-9"},{"key":"10.1124\/jpet.103.050682_bib22","doi-asserted-by":"crossref","unstructured":"Mansour A, Hoversten MT, Taylor LP, Watson SJ, and Akil H (1995) The cloned \u03bc, \u03b4 and \u03ba receptors and their endogenous ligands: evidence for two opioid peptide recognition cores. Brain Res 700: 89\u201398.","DOI":"10.1016\/0006-8993(95)00928-J"},{"key":"10.1124\/jpet.103.050682_bib23","doi-asserted-by":"crossref","unstructured":"Manzanares J, Lookingland KJ, and Moore KE (1991) \u03ba Opioid receptor-mediated regulation of dopaminergic neurons in the rat brain. J Pharmacol Exp Ther 256: 500\u2013505.","DOI":"10.1016\/S0022-3565(25)23043-9"},{"key":"10.1124\/jpet.103.050682_bib24","doi-asserted-by":"crossref","unstructured":"Mathieu-Kia AM, Fan LQ, Kreek MJ, Simon EJ, and Hiller JM (2001) \u03bc-, \u03b4- and \u03ba-opioid receptor populations are differentially altered in distinct areas of postmortem brains of Alzheimer\u2019s disease patients. Brain Res 893: 121\u2013134.","DOI":"10.1016\/S0006-8993(00)03302-3"},{"key":"10.1124\/jpet.103.050682_bib25","doi-asserted-by":"crossref","unstructured":"Moore MR and Black PM (1991) Neuropeptides. Neurosurg Rev 14: 97\u2013110.","DOI":"10.1007\/BF00313031"},{"key":"10.1124\/jpet.103.050682_bib26","doi-asserted-by":"crossref","unstructured":"Portenoy RK, Caraceni A, Cherny NI, Goldblum R, Ingham J, Inturrisi CE, Johnson JH, Lapin J, Tiseo PJ, and Kreek MJ (1999) Dynorphin A(1\u201313) analgesia in opioid-treated patients with chronic pain: a controlled pilot study. Clin Drug Investig 17: 33\u201342.","DOI":"10.2165\/00044011-199917010-00004"},{"key":"10.1124\/jpet.103.050682_bib27","doi-asserted-by":"crossref","unstructured":"Reid RL, Hoff JD, Yen SS, and Li CH (1981) Effects of exogenous \u03b2h-endorphin on pituitary hormone secretion and its disappearance rate in normal human subjects. J Clin Endocrinol Metab 52: 1179\u20131184.","DOI":"10.1210\/jcem-52-6-1179"},{"key":"10.1124\/jpet.103.050682_bib28","doi-asserted-by":"crossref","unstructured":"Spanagel R, Herz A, Bals-Kubik R, and Shippenberg TS (1991) \u03b2-Endorphin-induced locomotor stimulation and reinforcement are associated with an increase in dopamine release in the nucleus accumbens. Psychopharmacology 104: 51\u201356.","DOI":"10.1007\/BF02244553"},{"key":"10.1124\/jpet.103.050682_bib29","doi-asserted-by":"crossref","unstructured":"Spanagel R, Herz A, and Shippenberg TS (1990) The effects of opioid peptides on dopamine release in the nucleus accumbens: an in vivo microdialysis study. J Neurochem 55: 1734\u20131740.","DOI":"10.1111\/j.1471-4159.1990.tb04963.x"},{"key":"10.1124\/jpet.103.050682_bib30","doi-asserted-by":"crossref","unstructured":"Specker S, Wananukul W, Hatsukami D, Nolin K, Hooke L, Kreek MJ, and Pentel PR (1998) Effects of dynorphin A(1\u201313) on opiate withdrawal in humans. Psychopharmacology 137: 326\u2013332.","DOI":"10.1007\/s002130050626"},{"key":"10.1124\/jpet.103.050682_bib31","doi-asserted-by":"crossref","unstructured":"Staley JK, Rothman RB, Rice KC, Partilla J, and Mash DC (1997) \u03ba2 Opioid receptors in limbic areas of the human brain are upregulated by cocaine in fatal overdose victims. J Neurosci 17: 8225\u20138233.","DOI":"10.1523\/JNEUROSCI.17-21-08225.1997"},{"key":"10.1124\/jpet.103.050682_bib32","doi-asserted-by":"crossref","unstructured":"Svingos AL, Chavkin C, Colago EE, and Pickel VM (2001b) Major coexpression of \u03ba-opioid receptors and the dopamine transporter in nucleus accumbens axonal profiles. Synapse 42: 185\u2013192.","DOI":"10.1002\/syn.10005"},{"key":"10.1124\/jpet.103.050682_bib33","doi-asserted-by":"crossref","unstructured":"Svingos AL, Garzon M, Colago EE, and Pickel VM (2001a) \u03bc-Opioid receptors in the ventral tegmental area are targeted to presynaptically and directly modulate mesocortical projection neurons. Synapse 41: 221\u2013229.","DOI":"10.1002\/syn.1079"},{"key":"10.1124\/jpet.103.050682_bib34","doi-asserted-by":"crossref","unstructured":"Unterwald EM, Rubenfeld JM, and Kreek MJ (1994) Repeated cocaine administration upregulates \u03ba and \u03bc, but not \u03b4, opioid receptors. Neuroreport 5: 1613\u20131616.","DOI":"10.1097\/00001756-199408150-00018"},{"key":"10.1124\/jpet.103.050682_bib35","doi-asserted-by":"crossref","unstructured":"Wang GJ, Volkow ND, Fowler JS, Logan J, Abumrad NN, Hitzemann RJ, Pappas NS, and Pascani K (1997) Dopamine D2 receptor availability in opiate-dependent subjects before and after naloxone-precipitated withdrawal. Neuropsychopharmacology 16: 174\u2013182.","DOI":"10.1016\/S0893-133X(96)00184-4"},{"key":"10.1124\/jpet.103.050682_bib36","doi-asserted-by":"crossref","unstructured":"Wen HL and Ho WK (1982) Suppression of withdrawal symptoms by dynorphin in heroin addicts. Eur J Pharmacol 82: 183\u2013186.","DOI":"10.1016\/0014-2999(82)90509-X"},{"key":"10.1124\/jpet.103.050682_bib37","doi-asserted-by":"crossref","unstructured":"Yu J, Butelman ER, Woods JH, Chait BT, and Kreek MJ (1996) In vitro biotransformation of dynorphin A (1\u201317) is similar in human and rhesus monkey blood as studied by matrix-assisted laser desorption\/ionization mass spectrometry. J Pharmacol Exp Ther 279: 507\u2013514.","DOI":"10.1016\/S0022-3565(25)21157-0"},{"key":"10.1124\/jpet.103.050682_bib38","doi-asserted-by":"crossref","unstructured":"Zubieta JK, Gorelick DA, Stauffer R, Ravert HT, Dannals RF, and Frost JJ (1996) Increased \u03bc opioid receptor binding detected by PET in cocaine-dependent men is associated with cocaine craving. Nat Med 2: 1225\u20131229.","DOI":"10.1038\/nm1196-1225"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524308407?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524308407?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.103.050682","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T14:28:52Z","timestamp":1739975332000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524308407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,8]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2003,8]]}},"alternative-id":["S0022356524308407"],"URL":"https:\/\/doi.org\/10.1124\/jpet.103.050682","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2003,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Suppressed Prolactin Response to Dynorphin A1\u201313 in Methadone-Maintained Versus Control Subjects","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.103.050682","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2003 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}